<DOC>
	<DOCNO>NCT01437475</DOCNO>
	<brief_summary>HBV vaccination paramount importance among HIV positive person due increase risk infection disease progression . The widely use ENGERIX B vaccine reach low rate vaccination ( 20-70 % ) among HIV positive vaccinee ( compare 90 % normal population ) . Sci-B-Vac novel vaccine contain 3 antigen therefore immunogenic ( opposed one ENGERIX B ) . Its use associate higher rapid vaccination rate . Therefore , theoretical advantage HIV positive individual .</brief_summary>
	<brief_title>Efficiency Hepatitis B Sci-B-Vac Vaccine HIV Positive Patients</brief_title>
	<detailed_description>A cohort 100 HIV positive , HBV negative individual vaccinate HBV prospectively give 3 dos Sci-B-Vac 0 , 1 6 month . HBV antibodies check one month every dose give .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HBV negative HIV positive individual Above age 18 Treated TASMC Aids clinic , sign inform consent never vaccinate HBV Pregnant woman HBV positivity Previous HBV vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>HBV</keyword>
	<keyword>HIV</keyword>
	<keyword>Immunization</keyword>
	<keyword>HBV Immunization rate among HIV positive individual</keyword>
</DOC>